Since activation of NF-κB leads to inflammation that in turn is involved in the pathogenesis of many diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease [6], much attention has focused on the development of anti-inflammatory drugs targeting NF-κB [7]. The gene discussed is NFKB1; the disease is asthma.